UK Companies House feature
HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED
Profile
- Company number
- 07680243
- Status
- Active
- Incorporation
- 2011-06-23
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Accounts
Pending extraction
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company has net liabilities at 31 December 2024 of $2,359k (2023: net liabilities $18k). The Company has a letter of support in place from its ultimate parent company, Hikma, which states that, should it be required, Hikma will provide financial support to the Company for additional funding or to enable it to discharge its liabilities as they fall due for the foreseeable future. The Directors have assessed the ability of Hikma to provide that support and, on that basis, have concluded that the application of the going concern basis of preparation of the financial statements is appropriate.”
Subsidiaries
- Hikma d.o.o. · 100% held · Croatia · R&D center
- Hikma Services India Private Limited · 0.01% held · India
Significant events
- “During the year, the Company opened Hikma Pharmaceuticals International Limited, London, Geneva Branch (the "Swiss Branch") to supervise the global manufacturing and distribution of certain pharmaceutical products...”
- “In September 2024, the Company acquired a new subsidiary, an R&D center located in Zagreb, Croatia, as part of the Group's acquisition of the Xellia business.”
- “While the Company became a holding company during the year, its primary activities continue to relate to the wholesale distribution of medicinal products in the United Kingdom.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 21 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MIDDLEMIST, Helen | Secretary | 2022-07-18 | — | — |
| AL KURDI, Areb | Director | 2022-08-15 | Oct 1974 | Jordanian |
| VERISSIMO, Goncalo Pina Pereira | Director | 2025-03-25 | Nov 1977 | Portuguese |
Show 21 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| SPEIRS, Peter Alexander | Secretary | 2011-06-23 | 2022-06-15 |
| ABDEL-HAFEZ, Maen Abdel-Hamid Abdullah | Director | 2011-07-04 | 2014-11-04 |
| ARKHAQA, Hussein | Director | 2011-06-23 | 2014-11-04 |
| ASFEHA, Abrehet | Director | 2011-10-17 | 2014-11-04 |
| ATWAL, Gurpal Singh | Director | 2019-09-02 | 2022-02-11 |
| ATWAL, Gurpal Singh | Director | 2011-07-04 | 2016-09-07 |
| AWAD, Basel Ibrahim Bakir, Dr | Director | 2017-01-17 | 2019-09-02 |
| CREASE, Thomas Michael | Director | 2014-11-04 | 2015-01-05 |
| DARWAZAH, Tareq Mazen Samih | Director | 2011-07-04 | 2014-11-04 |
| HANSEN, Joanna Elizabeth | Director | 2020-03-30 | 2025-03-25 |
| HOFFMANN, Brian Scott | Director | 2016-08-25 | 2018-04-16 |
| HYDE, Jane Celia | Director | 2016-04-12 | 2016-09-07 |
| KHOURI, Bana | Director | 2022-04-01 | 2025-03-25 |
| MASARWEH, Natheer | Director | 2017-01-17 | 2019-09-02 |
| MIDDLEMIST, Helen | Director | 2022-07-18 | 2025-03-25 |
| MISHLAWI, Riad | Director | 2016-06-15 | 2019-09-02 |
| RAHMANI, Nassim | Director | 2022-12-07 | 2025-03-25 |
| RAYA, Michael Alex | Director | 2016-10-07 | 2017-12-31 |
| SAVASTANO, Frank Louis | Director | 2016-09-09 | 2019-09-02 |
| SPEIRS, Peter Alexander | Director | 2018-04-16 | 2022-06-15 |
| SPEIRS, Peter Alexander | Director | 2014-11-04 | 2016-09-07 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | Corporate entity | Shares 75–100% | 2016-06-25 | Ceased 2017-06-28 |
| Hikma Uk Limited | Corporate entity | Shares 75–100% | 2016-05-25 | Active |
Filing timeline
Last 20 of 100 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2025-10-04 | AA | accounts | accounts with accounts type full |
| 2025-09-02 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-03-26 | AP01 | officers | appoint person director company with name date |
| 2025-03-26 | TM01 | officers | termination director company with name termination date |
| 2025-03-26 | TM01 | officers | termination director company with name termination date |
| 2025-03-26 | TM01 | officers | termination director company with name termination date |
| 2025-03-26 | TM01 | officers | termination director company with name termination date |
| 2024-09-03 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-09-02 | CH01 | officers | change person director company with change date |
| 2024-07-26 | AA | accounts | accounts with accounts type full |
| 2023-11-24 | AA | accounts | accounts with accounts type full |
| 2023-09-08 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-12-08 | AP01 | officers | appoint person director company with name date |
| 2022-10-01 | AA | accounts | accounts with accounts type full |
| 2022-09-29 | SH19 | capital | capital statement capital company with date currency figure |
| 2022-09-29 | SH20 | capital | legacy |
| 2022-09-29 | CAP-SS | insolvency | legacy |
| 2022-09-29 | RESOLUTIONS | resolution | resolution |
| 2022-09-28 | SH01 | capital | capital allotment shares |
| 2022-09-13 | CS01 | confirmation-statement | confirmation statement with no updates |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory